Diligence memo · auto-generated · as of July 2, 2026
Morphic Holding, Inc.
Morphic Holding, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Morphic Holding, Inc. operates in Biotechnology, based in WALTHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Morphic Holding, Inc. has raised $201M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $100M on 2023-02-15.
Most recent recorded round closed around 2023-02-15.
Valuation (modeled)modeled
Provath models Morphic Holding, Inc. at approximately $1.5B (range $309M–$2.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.04× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 40 months.
Last raise 3.4 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Biotechnology peers (4293 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Genleap Ai Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.